Articles On Neuren Pharmaceuticals (ASX:NEU)

Mach 7 announces patent infringement lawsuit settled in its favour Lumos Diagnostics tanks after device submission for FebriDX rejected by US FDA Three companies announce major milestones in clinical trials Healthcare and life sciences e...

Neuren Pharmaceuticals (ASX: NEU) has announced that its Phase 2 clinical trial of NNZ-2591 in Angelman syndrome (AS) is open for enrolment.

Neuren Pharmaceuticals (NEU) opens its Phase Two clinical trial of its NNZ-2591 drug in Angelman syndrome (AS) for enrollment The trial is being conducted at three hospitals in Brisbane, Melbourne and Sydney under an investigational new dr...

Neuren’s Phase 2 clinical trial is now open for enrolment Neuroscientific submits an ethics approval request for Phase 1 trial Cannabis play Little Green Pharma signs $2m supply deal Neurological disorders specialist Neuren Pharmaceutical...

ShareCafeEvening Report: 8 July, 2022 by Lauren Evans   The Australian sharemarket had its best week since mid-March as recession fears eased. Friday’s session was spent in positive territory thanks to strong gains in the resources space. E...

Neuren Pharmaceuticals (NEU) appoints Liza A Squires to the new position of Chief Medical Officer in the United States Dr Squires is a physician in general paediatrics and neurology with special competence in child neurology Over the past...

Highlights Firebrick secures patent in Malaysia for Nasodine® Nasal Spray as a treatment and preventative for common cold Nasodine is now protected in 26 countries, with China, Singapore, Japan, and Canada on the pending list Nasodine...

Highlights The benchmark index ASX200 was 0.037% lower at 7146.200 points at 11:10 AM AEST today. Seven sectors were seen trading in the red in the early morning trading hours on Tuesday (24 May). The losses were led by the informatio...

Highlights Neuren Pharmaceuticals focuses on developing new drug therapies for serious neurological disorders Trofinetide and NNZ-2591 are two new drug candidates for Neuren The Neuren share price has gained nearly 197% over the last...

Megaport gets support of major investment firms increasing holdings Gold Road Resources increases stake in DGO Gold as part of takeover offer Milford Asset Management shows confidence in Neuren Pharmaceuticals Trading Places is Stockhead...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in ASX health stocks. Good news for coffee lovers, particularly those w...

Neuren Pharmaceuticals (ASX:NEU) has received US FDA approval to proceed with the Phase 2 trial of NNZ-2591 in Pitt Hopkins syndrome.

Highlights The Australian healthcare sector includes companies engaged in biotechnology and research, food and drug retailing, health care equipment, service providers, and pharmaceuticals. On a YTD basis, the healthcare index is runni...

Highlights The benchmark ASX 200 was trading 0.15% up at 7,409.8 in the first 15 minutes of trading. The energy sector is down amid a retracement in crude oil prices. Premier Investments has declared a record interim dividend of 46 ce...

Neuren Pharmaceuticals (NEU) has approval from the US Food and Drug Administration (FDA) to proceed with Phase 2 trials of its NNZ-2951 drug, which is used to treat Pitt Hopkins syndrome Neuren has also recently received FDA approval to pr...

Neuren Pharmaceuticals (NEU) receives the all clear from the US Food and Drug Administration (FDA) to commence phase two trials of its drug, NNZ-2591, on Phelan-McDermid syndrome (PMS) The trial will be conducted across four hospitals in U...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. At the start of trade on Frida...

Neuren Pharmaceuticals (ASX:NEU) has announced it has received approval from the Human Research Ethics Committee for its Phase 2 clinical trial of NNZ-2591 in Angelman syndrome.

Neuren Pharmaceuticals (NEU) is granted ethics approval to move ahead with its phase two clinical trial for a drug to treat Angelman syndrome The Human Research Ethics Committee’s approval covers three sites in Australia for the clinical t...

Highlights Several ASX stocks have returned over 100% to shareholders in the past year. Such stocks are known as multibaggers. PLS, NEU, and CNB are a few big names which have given attractive returns. Despite the ASX...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Neuren Pharmaceuticals (ASX:NEU) sats it has received approval from the US FDA to proceed with the Phase 2 trial of NNZ-2591 in Angelman syndrome.

The S&P/ASX 200 Pharmaceuticals & Biotechnology index (AXPBKD) is down 2.7% in the past year, but this one ASX biotech share could be a winner. The share has gained 188% in the past year, and 78% in the past six months. So which...

Neuren Pharmaceuticals (NEU) receives approval from the US Food and Drug Administration to proceed with the Phase 2 trial of NNZ-2591 in Angelman Syndrome The trial will be conducted at three hospitals across Australia, enrolling up to 20...

Highlights  Despite the ASX 200 trading on an uncertain note in the recent past, some stocks have given over 100% past year returns. The stocks with over 100% returns are called multibaggers stocks. PLS, UWL, NEU, AVR, and HXL are few...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. During his Australian Open quar...

Healthcare and life sciences expert Scott Power,who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. The Australian Open has kicked o...

ASX investors evidently shrugged off omicron fears in December, with the last month of the 2021 being the second best of the year. Ultimately, the market finished 2021 13% higher than it started. Patience pays off, unless you got in at the...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price has more than doubled in less than a month. The biopharmaceutical company’s share price has gained 102%, shooting from $1.80 at the end of last month to $3.64 at the time of writing. E...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

While the S&P/ASX 200 Index (ASX: XJO) hasn’t provided much of a Santa rally this year, there are a number of ASX-listed shares that are still feeling merry this December. Taking a look at the data, 20 companies on the ASX with a mark...

Shareholders of Dimerix (ASX:DXB) got an early Christmas present with the company telling them its Phase 3 clinical trial testing its DMX-200 drug against COVID-19 pneumonia respiratory complications in Europe was on track. The study (REMAP...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It’s been a...

There were few major catalysts on Thursday, as the ASX traded flat in a relatively cruisy session following some solid gains this week. Broadly speaking, the ASX has tracked global stock markets higher after a rocky selloff last week that f...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Rett Syndrome is a rare genetic neurological disorder that affects the way the brain develops, causing a progressive loss of motor skills and speech. It’s a form of autism that primarily affects girls, or about one in every 10,000 to 15,000...

The ASX finished 0.67% higher, marking the best performance by the Australian bourse since early October. Almost all sectors finished higher with energy and tech – two sectors under siege in recent weeks – recording gains of 2.07% and 1.9%...

The share market climbed for a third day, adding to gains after the Reserve Bank appeared to open the door to a rate rise next year. The S&P/ASX 200 sealed its longest winning run in more than a month with an advance of 69 points or...

Highlights Newly listed companyRocketBoots declined as much as 17.5% on ASX debut. Zip Co surged more than 9% on strong business growth in November. Neuren Pharma spiked over 100% on positive trial results for its drug Trofinetide....

Highlights The ASX 200 traded higher by 0.6% by mid-session on Tuesday. Barring utilities and materials, all sectors traded in the green zone. Travel stocks surged on easing concerns about the Omicron variant. Newly listed company Ro...

Neuren Pharmaceuticals’ (NEU) partner has announced positive top-line results from a phase three study on Rett syndrome Acadia Pharmaceuticals’ phase three “Lavender” study evaluated the efficacy and safety of investigational drug trofinet...

The share market climbed to its highest in a week before tempering gains ahead of this afternoon’s Reserve Bank policy update. The S&P/ASX 200 trimmed a 67-point opening rally to 48 points or 0.66 per cent at mid-session. Travel s...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is soaring to yearly highs on the back of positive phase three clinical trial results. Shares are currently swapping hands at $3.40 apiece, up exactly 100% from yesterday’s close. Let...

The ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader index which is down by 0.40%. The stock price of Neuren Pharmaceuticals (ASX:NEU) is up 100% this morning after the company announced its North...

Neuren Pharmaceuticals (ASX:NEU) has reported that its partner for trofinetide in North America, Acadia Pharmaceuticals, has announced positive top-line results from a Phase 3 study.

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Going into...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...